eNLife Research raises ₹6 crore to develop AI-based blood test for Alzheimers detection

In July 2026, Bengaluru-based deep-tech startup eNLife Research raised over INR 6 crore in a seed funding round led by Piper Serica VC Fund to support the development of its artificial intelligence (AI)-driven diagnostic platform for Alzheimer’s disease and other neurodegenerative disorders.

The company further stated that the funding will be used to build and validate its blood-based biomarker platform, expand its Bengaluru-based research and development team, and advance its first diagnostic assay from prototype to clinical-grade validation. According to the company, eNLife is actively working to make early Alzheimer’s detection more accessible in India before conventional diagnostic methods identify the disease.

The company is also developing assays that are capable of simultaneously tracking 25 to 100 biological markers in order to identify multiple forms of dementia and other neurodegenerative diseases before the onset of clinical symptoms.

Furthermore, the company states that, unlike PET scans, MRI scans, and cerebrospinal fluid analysis, which are invasive, expensive, and generally used during later stages of diagnosis, its blood test can be administered through routine diagnostic centers and can deliver results within two to five hours. The company’s AI platform is being trained to identify correlations between biomarkers, enabling the detection of disease progression before clinical symptoms even emerge.

eNLife is further collaborating with researchers associated with the Indian Institute of Science (IISc), the National Institute of Mental Health and Neurosciences (NIMHANS), the Tata Institute of Fundamental Research (TIFR), Hyderabad, and the Centre for Brain Research (CBR), Bengaluru, to develop India-specific biomarker datasets.

Impact on the Healthcare Industry

The healthcare sector is opening up to long-term and end-of-life care for the elderly, and this shift is meaningful, given the significant increase in the elderly population, along with the realities shaped by increasing nuclear families, professional migration, and evolving social structures.

The healthcare industry is increasingly focusing on dementia care, with a growing emphasis on long-term and end-of-life care for the elderly. This shift is driven by the increasing elderly population and the need for a more structured approach to elder care. The industry is evolving to provide better care and support for individuals living with Alzheimer's and other forms of dementia.

The dementia care workforce includes a variety of healthcare and social service professionals, each contributing to the care of people living with dementia. There are significant gaps in knowledge regarding the characteristics of this workforce, their training, and their knowledge in dementia care. The healthcare industry is actively responding to these challenges posed by Alzheimer's disease through various initiatives, including telemedicine, research, and rapid integration with AI and ML tools.

Impact on the Alzheimer's Disease Diagnostics Market

The global alzheimer’s disease diagnostics market size accounted for USD 9.40 billion in 2025 and is predicted to increase from USD 10.42 billion in 2026 to approximately USD 26.21 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035.

According to Precedence Research, the incidence of Alzheimer's disease is increasing rapidly, and the demand for early and accurate diagnosis of Alzheimer's disease is on the rise, which is fueling the rapid growth of the market. Continuous improvements in blood-based biomarker assays, CSF testing, and AI-driven diagnostic platforms are driving rapid transformations in the market.

Researchers have now developed machine learning models that detect subtle changes in how people speak, such as their speech rate, word choice, and pausing patterns, in order to identify early Alzheimer’s signs and predict mild cognitive impairment. This consistency is particularly valuable in dementia care because early signs of neurodegeneration, like slight atrophy patterns and subtle changes in brain connectivity, are easy to overlook in a visual scan but critical to catch early. This is where AI tools prove to be beneficial. 

Impact on the Alzheimer's Drug Market

The global alzheimer’s drug market size accounted for USD 4.18 billion in 2025 and is predicted to increase from USD 4.43 billion in 2026 to approximately USD 7.53 billion by 2035, expanding at a CAGR of 6.06% from 2026 to 2035.

According to Precedence Research, the market is undergoing a transformative era marked by scientific breakthroughs, regulatory shifts, and high levels of investment in AI and ML tools. Although several medicines are available to help manage symptoms of Alzheimer’s disease, there is currently no approved treatment capable of stopping the underlying disease process. Researchers believe artificial intelligence could help bridge that gap by identifying more effective drug candidates and reducing the time required for early-stage discovery.

AI tools are completely revolutionizing the development of Alzheimer's drugs by helping in accelerating the discovery of new drug targets and optimizing lead molecules. These tools make use of machine learning and deep learning algorithms in order to analyze complex biological data, identify potential drug candidates, and streamline clinical trials. AI’s ability to analyze vast amounts of data and pinpoint biomarkers makes it an ideal healthcare ally in today’s market landscape. 

Expert Opinion

Commenting on the funding, Dr Deepak Kumaran Nair, Co-founder and Chief Executive Officer, eNLife Research, said,

“The biggest failure of Alzheimer’s care today isn’t the absence of treatments in trials; it’s that we find patients a decade too late to use them. Every diagnostic model the world has built so far was designed on Western cohorts, at hospital price points that don’t work for India. We started eNLife to close both gaps at once: detect the disease at the molecular stage, far ahead of the symptomatic stage, and do it through a simple blood draw that is both accessible and affordable to the whole of the Indian population. This funding lets us move that ambition from the lab bench to a validated product, and having an investor like Piper Serica, who understood the science as much as the market, gives us the conviction to forge ahead with our mission.”